GlassScriptPhysician profile
Curtis Campbell
NPI 1770975278
$1,498.35
in general payments reported to CMS, 2019-2025
25 companies · $64.88 in 2025
The $64.88 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $95.06 · 2020: $24.69 · 2022: $202 · 2023: $486 · 2024: $626 · 2025: $64.88.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,177.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,176.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $281.69 | 2019-2024 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $173.10 | 2019-2024 | Farxiga, Breztri |
| Dexcom, INC. | $122.54 | 2023-2025 | Dexcom G6 Transmitter |
| Amgen INC. | $92.98 | 2023-2024 | Otezla, Repatha |
| Novo Nordisk INC | $85.61 | 2020-2024 | Ozempic, Wegovy, Rybelsus |
| Teva Pharmaceuticals USA, INC. | $85.54 | 2022-2024 | Austedo Xr, Ajovy |
| Otsuka America Pharmaceutical, INC. | $79.64 | 2024 | Rexulti |
| Exact Sciences Corporation | $76.23 | 2023-2024 | Cologuard Collection Kit |
| Abbvie INC. | $66.35 | 2023-2024 | Synthroid, Vraylar |
| Boehringer Ingelheim Pharmaceuticals, INC. | $62.71 | 2023-2024 | Jardiance, Ofev |
| Novartis Pharmaceuticals Corporation | $47.55 | 2022-2023 | |
| Abbott Laboratories | $46.91 | 2024 | Freestyle Libre 3 |
| Idorsia Pharmaceuticals US INC | $44.14 | 2023-2024 | Quviviq |
| Bayer Healthcare Pharmaceuticals INC. | $34.83 | 2022 | |
| Glaxosmithkline, LLC. | $32.72 | 2022-2023 | Shingrix, Pediarix, Bexsero |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $28.89 | 2024 | |
| Sanofi Pasteur INC. | $20.50 | 2023 | |
| Irhythm Technologies, INC. | $17.99 | 2022 | |
| Merck Sharp & Dohme LLC | $17.35 | 2023 | Belsomra |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $14.75 | 2025 | Caplyta |
| E.R. Squibb & Sons, L.L.C. | $13.80 | 2019 | |
| Bioventus LLC | $13.66 | 2024 | Exogen Ultrasound Bone Healing System |
| Janssen Pharmaceuticals, INC | $13.56 | 2023 | Xarelto |
| Amneal Pharmaceuticals LLC | $13.56 | 2023 | Unithroid |
| Gilead Sciences, INC. | $11.75 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Curtis Campbell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.